Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer

Shimizu, Kimihiro; Yoshida, Junji; Nagai, Kanji; Nishimura, Mitsuyo; Ishii, Genichiro; Morishita, Yasuo; Nishiwaki, Yutaka

doi:10.1016/j.jtcvs.2004.11.021

Cited by 182 publications

(162 citation statements)

References 25 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…The overall incidence of VPI in NSCLC has been documented as 11.5-26.8% (4,15). Considering that VPI occurs only when tumor-pleura contact is direct, the exact incidence of the peripheral tumors has not been reported in previous studies.…”

Section: Discussionmentioning

confidence: 99%

“…As suggested by Maeyashiki et al (19), the maximum dimension of consolidation in part-solid GGNs was a significant predictor of lymph node positive status and poor prognosis. Shimizu and colleagues (4) suggested that tumors with VPI had usually moderate or worse differentiation and had a higher scar grade (tumors had fibroblastic tissue with amount of collagen fibers). In our case series, larger consolidation area was associated with higher rate of VPI.…”

Section: Discussionmentioning

confidence: 99%

“…Osaki et al (2) and Shimizu et al (3,4) reported approximately 10-30% worse 5-year survival in tumors with VPI compared to those without VPI (45.6-49.8% in VPI group and 60.7-79.0% in non-VPI group). In the 7 th edition of TNM classification for NSCLC, VPI increases the T staging factor of a tumor from T1 to T2 and upstages the tumor, even when ≤3 cm, from stage IA to stage IB (5).…”

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

Zhao¹,

Xie²,

Zhang³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Visceral pleural invasion (VPI) had been demonstrated as an aggressive sign in non-small cell lung cancers (NSCLC). However, its incidence and clinical relevance in early lung cancer showing ground glass nodules (GGNs) has not been clarified. Results: Out of 156 enrolled patients, 38 had pathologically confirmed VPI. The incidence of VPI was 41.5% (27/65) if the tumor diameter was larger than 2.0 cm and 14.3% (13/91) if diameter was smaller than 2.0 cm (P<0.001). Further, the incidence was 17.4% (12/69) in pure GGNs and 32.2% (28/87) in part-solid GGNs (P=0.040). The tumor size and the nodule nodule-pleural relationship were significant predictors of positive VPI. In cases with pleural indentation, attachment, and closeness, the incidence was 38.1%, 25.5%, and 5.3%, respectively (P=0.001). All cases were PL0 and PL1, with no PL2 cases observed.Conclusions: Although VPI was visible in both pure/mix GGNs, it was more common in larger (>2 cm) GGNs. The radiographic findings of nodule abutment or a pleural tag did not reliably predict or exclude VPI. In patients with GGNs, a low rate of PL2 invasion may be observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

Zhao¹,

Xie²,

Zhang³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…For instance, mediastinal lymph node involvement and the number of metastatic lymph nodes are important negative prognostic factor in surgically resected stage IIIA NSCLC [2]. Additionally, visceral pleural invasion was observed more frequently in biologically aggressive NSCLCs, and by multivariate analysis, this invasion proved to be a significant independent predictor of grim prognosis, with or without lymph node involvement [3]. Therefore, in most NSCLC cases, the therapeutic strategy is based on the tumor stage and on the performance status of the patient at diagnosis.…”

Section: Introductionmentioning

confidence: 95%

On the pharmacogenetics of non-small cell lung cancer treatment

Santarpía

Rolfo

Peters

et al. 2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Introduction. Despite many clinical efforts, non-small-cell lung cancer (NSCLC) has a dismal 5-year survival rate of 16%, and high incidence of recurrence. The success of biologically targeted agents, as well as the activity of well-established chemotherapeutic regimens, has been limited by inherited/ acquired resistance, and biomarkers to adapt the prescription of anticancer drugs to patients' features are urgently warranted. Areas covered. In oncology, pharmacogenetics should provide the way to select patients who may benefit from a specific therapy that best match the individual and tumor genetic profile, thus allowing maximum activity and minimal toxicity. The present review summarizes the main findings on NSCLC pharmacogenetics, critically reappraising the most important studies on polymorphisms correlated with outcome of pemetrexed and EGFR-inhibitors, and provides perspective on clinical application of genomic tests for treatment decision-making. Expert Opinion. A major challenge in NSCLC is the identification of subgroups of diseases/patients that will truly benefit from specific treatments. Ideally, convenient and minimally invasive tests to decipher biomarkers of chemosensitivity/resistance and toxicity should be developed alongside novel anticancer treatments. Integration with the latest generation of whole-genome analyses and liquid biopsies as well as prospective validation in large cohorts of patients will overcome the limitations of the traditional pharmacogenetic approaches. ARTICLE HISTORY

show abstract

“…We further analyzed the characteristic features of tumor cells among patients who underwent anatomic resection, in order to identify its effect on disease-free and overall survival rates. Previous studies had reported that several pathological factors were related to survival rate; these factors include visceral pleural invasion, [19][20][21][22] vascular invasion, [23] perineural invasion, [24][25][26] histologic grade, [27] and nuclear atypia. [28] Our multivariate analysis indicated that only perineural invasion had a significant effect on disease-free and overall survival rates among N2 NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer

Hsieh

Liu

et al. 2015

Biomed J

View full text Add to dashboard Cite

Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer

Abstract: Visceral pleural invasion is a significant poor-prognostic factor, regardless of N status. Our analyses indicated that visceral pleural invasion is an independent indicator of non-small cell lung cancer invasiveness and aggressiveness.

Cited by 182 publications

References 25 publications

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

On the pharmacogenetics of non-small cell lung cancer treatment

Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer

Contact Info

Product

Resources

About